Adaptive Biotechnologies Stock Price, News & Analysis (NASDAQ:ADPT)

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADPT, but not buy additional shares or sell existing shares.
View ADPT analyst ratings or view top-rated stocks.

5 brokers have issued 1-year target prices for Adaptive Biotechnologies' shares. Their ADPT share price targets range from $6.00 to $15.00. On average, they predict the company's stock price to reach $9.50 in the next year. This suggests a possible upside of 116.9% from the stock's current price.
View analysts price targets for ADPT or view top-rated stocks among Wall Street analysts.

Adaptive Biotechnologies' stock was trading at $7.64 on January 1st, 2023. Since then, ADPT shares have decreased by 42.7% and is now trading at $4.38.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our ADPT earnings forecast.

Adaptive Biotechnologies Co. (NASDAQ:ADPT) issued its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.33) EPS for the quarter, hitting analysts' consensus estimates of ($0.33). The business earned $48.93 million during the quarter, compared to the consensus estimate of $44.87 million. Adaptive Biotechnologies had a negative trailing twelve-month return on equity of 47.63% and a negative net margin of 109.04%. The firm's quarterly revenue was up 12.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.37) EPS.

ETFs with the largest weight of Adaptive Biotechnologies (NASDAQ:ADPT) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and ETFMG Treatments Testing and Advancements ETF (GERM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Home Depot (HD), Inovio Pharmaceuticals (INO), PayPal (PYPL) and Tesla (TSLA).

(ADPT) raised $200 million in an initial public offering on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

Adaptive Biotechnologies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (7.96%), Sumitomo Mitsui Trust Holdings Inc. (4.54%), Massachusetts Financial Services Co. MA (1.36%), Federated Hermes Inc. (0.96%), Principal Financial Group Inc. (0.86%) and Northern Trust Corp (0.72%). Insiders that own company stock include Chad M Cohen, Chad M Cohen, Chad M Robins, Chad M Robins, Charles Sang, David E Goel, Egon Durban, Eric Dobmeier, Euclidean Capital Llc, Francis Lo, Global Investors Lp Viking, Harlan S Robins, Harlan S Robins, Julie Rubinstein, Jyoti Palaniappan, Kyle Piskel, Lance Baldo, Michael J Pellini, Michelle Renee Griffin, Nancy Louise Hill, Nitin Sood, R Mark Adams, Robert Hershberg, Sharon Benzeno, Stacy L Taylor and Tycho Peterson.
View institutional ownership trends.

Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.